Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6855010 | 0.88 | L3MBTL1 (0.39) | NFE2L2SMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL7646522 | 0.87 | NR3C2 (0.38) | NFE2L2SMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL27938323 | 0.84 | SMN1; SMN2 (0.40) | NFE2L2SMN1; SMN2NPC1RAB9AABCB1 | |
| SCHEMBL15212175 | 0.83 | NFE2L2 (0.39) | NFE2L2SMN1; SMN2NPC1RAB9AABCB1 | |
| SCHEMBL7912706 | 0.82 | KIF11 (0.41) | NFE2L2SMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL7541639 | 0.81 | KIF11 (0.40) | NFE2L2SMN1; SMN2NPC1RAB9AHIF1A | |
| SCHEMBL15212062 | 0.80 | KIF11 (0.40) | NFE2L2SMN1; SMN2NPC1RAB9AABCB1 | |
| SCHEMBL20675 | 0.79 | CYP19A1 (0.45) | NFE2L2SMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL16675115 | 0.78 | NFE2L2 (0.45) | NFE2L2SMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL15212075 | 0.77 | CNR1 (0.35) | NFE2L2SMN1; SMN2NPC1RAB9AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7355036-B2 | Two-stage protective groups for the synthesis of biopolymers | FEBIT AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-7094943-B2 | Solution phase biopolymer synthesis | Köster, Hubert (US) | 2006-08-22 | — | — | US | disclosed |
| US-7038103-B2 | Solution phase biopolymer synthesis | HUBERT KOSTER (CH) | 2006-05-02 | — | — | US | disclosed |
| US-20040197851-A1 | Two-stage protective groups for the synthesis of biopolymers | MR. CHRISTOPHER SEAGON, ESQ. (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20020016451-A1 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | CAPROTEC BIOANALYTICS GMBH (DE) | 2002-02-07 | — | — | US | disclosed |
| US-20020007048-A1 | Solution Phase Biopolymer Synthesis | CAPROTEC BIOANALYTICS GMBH (DE) | 2002-01-17 | — | — | US | disclosed |
| EP-1073668-A2 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | Köster, Hubert (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055718-A2 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | KOESTER HUBERT (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197851-A1 | Two-stage protective groups for the synthesis of biopolymers | CTRB2, OGG1, CPB2 | NFE2L2 124/4885SMN1; SMN2 933/4885NPC1 4560/4885 |
| US-20020007048-A1 | Solution Phase Biopolymer Synthesis | RNGTT, SGMS1, SPNS2 | NFE2L2 3880/4885SMN1; SMN2 585/4885NPC1 703/4885 |
| US-20020016451-A1 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | RNGTT, SGMS1, SPNS2 | NFE2L2 3880/4885SMN1; SMN2 585/4885NPC1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.